Initially, the American College of Rheumatology urged caution around the use of biosimilars. Information about the manufacturing process for a branded biologic is proprietary; a biosimilar manufacturer will not have access to the details of the process, so how could they guarantee their product would be the same? It is now well accepted by the scientific community that biosimilars are safe, and in February 2018 ACR published a white paper, “The Science Behind Biosimilars: Entering a New Era of Biologic Therapy,” 1 which aims to educate ACR members about and support the use of biosimilars.
- 1Bridges, S. Louis Jr., et al. “The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.” Arthritis and Rheumatology 70, no. 3 (March 2018): 334–44. https://www.rheumatology.org/Portals/0/Files/ACR-White-Paper-Science-Behind-Biosimilars.pdf